title: The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines.
abstract: Far-upstream element (FUSE)-binding protein 2 (FBP2) was a member of single-stranded DNA-binding protein family; it played an important role in regulating transcription and post-transcription and is involved in the regulation of C-MYC gene expression in liver tumors. However, the role of FBP2 in breast cancer and its mechanism has not been studied yet. Here, we discovered that FBP2 was up-regulated in breast cancer tissues and breast cancer cell lines. Moreover, immunohistochemistry analysis demonstrated that up-regulated FBP2 was highly associated with tumor grade, Ki-67, and poor prognosis, which was an independent prognostic factor for survival of breast cancer patients. At the cellular level, we found that FBP2 was correlated with cell cycle progression by accelerating G1/S transition, and knockdown of FBP2 could weaken cell proliferation, anchorage-independent cell growth, while enhancing the sensitivity of breast cancer cells to doxorubicin. More importantly, we found that activation of PI3K/AKT pathway could phosphorylate FBP2, and then make FBP2 shuttle from cytoplasm into the nucleus, which was the main mechanism of breast cancer cell proliferation and drug resistance. Taken together, our findings supported the notion that FBP2 might via PI3K/AKT pathway influence breast cancer progression and drug resistance, which might provide a new target for the design of anti-cancer drugs for breast cancer patients.
authors.affiliation: Department of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Ying-Ying
authors.initials: YY
authors.lastname: Wang
authors.affiliation: Department of Oncology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Gu
authors.affiliation: Department of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Qi-Chao
authors.initials: QC
authors.lastname: Ni
authors.affiliation: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Chun-Hui
authors.initials: CH
authors.lastname: Zhang
authors.affiliation: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Xia-Fei
authors.initials: XF
authors.lastname: Yu
authors.affiliation: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Li-Yi
authors.initials: LY
authors.lastname: Yang
authors.affiliation: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Zhi-Xian
authors.initials: ZX
authors.lastname: He
authors.affiliation: Department of Oncology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China. ntfymgx@163.com.
authors.forename: Guo-Xin
authors.initials: GX
authors.lastname: Mao
authors.affiliation: Department of Pathology, Nantong University Cancer Hospital, Nantong University, Nantong, 226001, Jiangsu, China. yangsy123648@163.com.
authors.forename: Shu-Yun
authors.initials: SY
authors.lastname: Yang
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D001940:Breast / Q000378:metabolism / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects*; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D016601:RNA-Binding Proteins / Q000378:metabolism*; D015996:Survival Rate; D015534:Trans-Activators / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; C105789:KHSRP protein, human; D016601:RNA-Binding Proteins; D015534:Trans-Activators; D004317:Doxorubicin
keywords: Breast cancer; Doxorubicin; FBP2; Prognosis; Proliferation; Resistance
references.citation: Proteomics. 2008 Dec;8(23-24):5086-96
references.pmid: 19003864
references.citation: Int J Mol Sci. 2013 Apr 15;14(4):8213-27
references.pmid: 23591839
references.citation: Cancer Discov. 2012 Mar;2(3):248-59
references.pmid: 22585995
references.citation: Biochem Pharmacol. 2012 May 15;83(10 ):1340-8
references.pmid: 22342288
references.citation: Oncogene. 2011 Oct 27;30(43):4437-46
references.pmid: 21532620
references.citation: Biochem Biophys Res Commun. 2012 Jun 15;422(4):727-31
references.pmid: 22618230
references.citation: Mol Biol Cell. 2012 Jul;23(14):2635-44
references.pmid: 22593207
references.citation: Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S17-27
references.pmid: 22443084
references.citation: J Thorac Oncol. 2012 Aug;7(8):1315-26
references.pmid: 22648207
references.citation: Cancer Res. 2009 Mar 15;69(6):2234-43
references.pmid: 19258502
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Cancer Lett. 2012 Oct 1;323(1):77-87
references.pmid: 22484466
references.citation: Cell Cycle. 2010 Dec 1;9(23):4666-73
references.pmid: 21099359
references.citation: BMC Cancer. 2008 Dec 16;8:369
references.pmid: 19087307
references.citation: Cancer Lett. 2013 Jan 28;328(2):353-61
references.pmid: 23104321
references.citation: Nat Med. 1997 Apr;3(4):447-50
references.pmid: 9095180
references.citation: J Neurotrauma. 2010 Feb;27(2):361-71
references.pmid: 19852587
references.citation: Clin Cancer Res. 2012 Nov 1;18(21):5856-64
references.pmid: 23082003
references.citation: Biochem Pharmacol. 2012 Nov 1;84(9):1154-63
references.pmid: 22902833
references.citation: Onkologie. 2013;36(11):650-5
references.pmid: 24192769
references.citation: Mol Cell. 2004 Jun 4;14(5):571-83
references.pmid: 15175153
references.citation: PLoS Biol. 2006 Dec;5(1):e5
references.pmid: 17177604
references.citation: PLoS One. 2013 May 07;8(5):e63404
references.pmid: 23667609
references.citation: J Biol Chem. 1996 Dec 6;271(49):31679-87
references.pmid: 8940189
references.citation: Development. 2002 Dec;129(24):5609-19
references.pmid: 12421702
references.citation: Int J Oncol. 2013 May;42(5):1833-41
references.pmid: 23525457
references.citation: J Biol Chem. 2004 Feb 13;279(7):5397-404
references.pmid: 14645243
references.citation: Neuropathol Appl Neurobiol. 2014 Feb;40(2):205-16
references.pmid: 24117486
references.citation: Mol Cell Biol. 2006 May;26(10):3695-706
references.pmid: 16648466
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Science. 2002 May 31;296(5573):1655-7
references.pmid: 12040186
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Int J Cancer. 2005 Mar 1;113(6):911-9
references.pmid: 15514971
references.citation: Oncogene. 2005 Jun 16;24(26):4281-92
references.pmid: 15806160